Clincosm LogoSign in Get a demo

Surgical Evaluation for Upper Extremity Lymphedema (BioBridge)

Sponsor
Fibralign Corporation (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05695924
Collaborator
Stanford University (Other)
60
Enrollment
1
Location
2
Arms
27
Anticipated Duration (Months)
2.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

To investigate whether the addition of Fibralign's BioBridge® Collagen Matrix (BioBridge) devices to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm.

Condition or Disease Intervention/Treatment Phase
  • Device: BioBridge® Collagen Matrix
  • Procedure: Vascularized Lymph Node Transfer (VLNT)
 N/A

Detailed Description

The proposed study utilizes Fibralign's BioBridge® Collagen Matrix (BioBridge), a sterile implantable biocompatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083.

The study will investigate whether addition of the BioBridge Collagen Matrix to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper extremity. This clinical study will also be used in support of IDE G200200 review conducted by the FDA.

Primary endpoint is the post surgical % change in excess limb volume, measured at 12 months following the surgical procedure.

Secondary endpoints are change in quality of life scores measured by LLIS and change in lymphatic function as measured by indocyanine green (ICG) fluorescence imaging.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective, randomized, control armProspective, randomized, control arm
Masking:
Single (Outcomes Assessor)
Masking Description:
Partially Blinded: Patients will be informed which group they are randomized into and given the option to opt out of the study. Investigators (other than surgeons conducting surgery) and study personnel involved in patient measurements will be unaware of the patient treatment option.
Primary Purpose:
Treatment
Official Title:
Prospective Evaluation of Nanofibrillar Collagen Scaffold (BioBridge®) as an Adjunct to Lymph Node Transplant for Upper Extremity Lymphedema
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
Jun 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: BioBridge treatment group

Vascularized Lymph Node Transplant surgery (VLNT) supplemented by BioBridge Collagen Matrix implantation

Device: BioBridge® Collagen Matrix
BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.

Procedure: Vascularized Lymph Node Transfer (VLNT)
Micro-surgical procedure for vascularized lymph node transfer (VLNT)
Active Comparator: Control group

Vascularized Lymph Node Transplant surgery (VLNT) only

Procedure: Vascularized Lymph Node Transfer (VLNT)
Micro-surgical procedure for vascularized lymph node transfer (VLNT)

Outcome Measures

Primary Outcome Measures

  1. Excess limb volume change [Baseline and 12 months after treatment]

    Change in % of (excess) limb volume in the intervention group relative to control group

Secondary Outcome Measures

  1. LLIS survey [Baseline and 12 months after treatment]

    Lymphedema-specific instrument to measure impairments, activity limitations, and participation restrictions in those living with any extremity lymphedema

  2. L-Dex bioimpedance spectroscopy. [Baseline and 12 months after treatment]

    Change in the Lymphedema Index (L-Dex) in the intervention group relative to control group. The L-Dex score has the requisite sensitivity and specificity to detect the differences in retained interstitial fluid that might discriminate the therapeutic responses of the treated patients. It has been established that the normal range of the L-Dex score is in the interval from -10 to +10 units; the higher score the more difference is in the retained interstitial fluid between the affected and unaffected limbs.

  3. Histology [Baseline and 12 months after treatment]

    Change in cutaneous histological architecture. The impact of treatment on the cutaneous histopathology will be evaluated through the use of an empirically derived scoring system and will be performed by a dermatopathologist.

  4. ICG fluorescence imaging [Baseline and 12 months after treatment]

    Change in lymphatic function assessed by ICG fluorescence imaging

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

The subject must be a breast cancer survivor, at least 3 years beyond completion of cancer therapy, free of clinical disease, and eligible for surgical intervention. Participants who are not able to safely undergo general anesthesia and/or perioperative care for VLNT are excluded.

  • Ages 18 to 75 years (inclusive)

  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2

  • Life expectancy > 2 years

  • Acquired (secondary) upper limb lymphedema secondary to breast cancer treatment

  • The participant must be eligible for surgical intervention

  • Swelling of 1 limb that is not completely reversed by elevation or compression

  • Stage I-II lymphedema at screening, based on the International Society of Lymphology (ISL) staging system

  • Participants must have no evidence of disease (NED), have completed breast cancer therapy 3 years prior to enrollment; use of endocrine therapy is allowed.

  • Completion of a full course of complete decongestive therapy (CDT), according to ISL guidelines at least 12 weeks prior to screening, including use of compression garments for at least 12 weeks without change in regimen

  • Willingness to comply with recommended regimen of self care, with consistent use of compression garments from screening through the entire study duration (through the safety follow up visit), excluding the first 3 weeks postoperatively where patients are required to not wear compression. Self bandaging, use of nighttime compression garments, and intermittent pneumatic compression devices are allowed, but the procedures and regimens are expected to remain consistent from screening though the entire study duration.

  • Consistent use of an appropriately sized compression garment for daytime use.

  • Limb volume (LV) in the affected limb and unaffected limb must be at least 10% of each other.

  • Evidence of abnormal bioimpedance ratio, if feasible, based upon unilateral disease: L Dex > 10 units.

  • Willingness and ability to comply with all study procedures, including measurement of skin biopsy, and preoperative and postoperative imaging studies.

  • Willingness and ability to understand, and to sign a written informed consent form document

Exclusion Criteria:

  • Edema arising from increased capillary filtration will be excluded (venous incompetence).

  • Inability to safely undergo general anesthesia and/or perioperative care related to vascularized lymph node transfer

  • Concurrent participation in a clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening or 5 times the drug's half life, whichever is longer

  • Recent initiation (≤ 12 weeks) of CDPT for lymphedema

  • Other medical condition that could lead to acute limb edema, such as (but not limited to) acute venous thrombosis or heart failure

  • Other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb (eg, pain, swelling, decreased range of motion)

  • History of clotting disorder (hypercoagulable state)

  • Chronic (persistent) infection in the affected limb

  • Infection of the lymphedema limb within 1 month prior to screening

  • Currently receiving chemotherapy or radiation therapy

  • Current evidence, or a history of malignancy within the past 3 years (except for non melanoma skin cancer or cervical cancer in situ treated with curative intent). If the participant has undergone cancer treatment, this must have been completed > 3 years prior to enrollment.

  • Significant or chronic renal insufficiency (defined as serum creatinine > 2.5 mg/dL or an estimated glomerular filtration rate [eGFR] < 30 mL/min at screening) or requires dialytic support

  • Hepatic dysfunction, defined as alanine transaminase (ALT) or aspartate transaminase (AST) levels > 3 × upper limit of the normal range (ULN) and/or bilirubin level > 2 × ULN at screening

  • Absolute neutrophil count < 1500 mm3 at screening

  • Hemoglobin concentration < 9 g/dL at screening

  • Body Mass Index (BMI) >35

  • Known sensitivity to porcine products

  • Anaphylaxis to iodine

  • Pregnancy or nursing

  • Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening

  • Any reason (in addition to those listed above) that, in the opinion of the investigator, precludes full participation in the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stanford University Stanford California United States 94305

Sponsors and Collaborators

  • Fibralign Corporation
  • Stanford University

Investigators

  • Study Director: Dung H Nguyen, MD, PharmD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Fibralign Corporation
ClinicalTrials.gov Identifier:
NCT05695924
Other Study ID Numbers:
  • IRB-67367
First Posted:
Jan 25, 2023
Last Update Posted:
Jan 25, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by Fibralign Corporation
Lymphedema
Edema
Additional relevant MeSH terms:
Lymphedema

Study Results

No Results Posted as of Jan 25, 2023